Previous Close | 4.1500 |
Open | 4.1300 |
Bid | 3.8800 x 1400 |
Ask | 7.1000 x 1300 |
Day's Range | 4.0900 - 4.5400 |
52 Week Range | 3.4100 - 7.3800 |
Volume | |
Avg. Volume | 78,618 |
Market Cap | 239.089M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | 27.94 |
EPS (TTM) | 0.1600 |
Earnings Date | Nov 10, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 6.90 |
Subscribe to Yahoo Finance Plus to view Fair Value for THRN
In this article, we will take a look at the 13 cheap new stocks to buy. To see more such companies, go directly to 5 Cheap New Stocks To Buy. Global markets were rattled by the market crash of 2022 whose reverberations are expected to affect equities for several months to come. However, prudent investors […]
Every investor in Thorne HealthTech, Inc. ( NASDAQ:THRN ) should be aware of the most powerful shareholder groups. The...
On January 3, 2023, the U.S. Circuit Court of Appeals for the Federal Circuit in Washington, D.C., issued a final ruling rendering the previously issued U.S. Patent No. 8,383,086 ("the '086 patent") to be unpatentable and therefore invalid. The '086 patent claim covered "The pharmaceutical composition . . . wherein nicotinamide riboside is isolated from a natural or synthetic source." The effect of the '086 patent was to provide broad patent protection of the nicotinamide riboside (NR) molecule